Pharvaris CMO exercises options, sells 14,166 shares

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Pharvaris N.V. Chief Medical Officer Lu Peng reported an exercise-and-sale transaction in company stock. On May 1, 2026, Peng exercised stock options to acquire 14,166 shares of common stock at an exercise price of $2.59 per share, then sold the same number of shares in open-market trades under a pre-arranged Rule 10b5-1 trading plan. The sales, executed as a cashless exercise, had weighted average prices around $30–$31 per share. Following these transactions, Peng directly holds 66,083 shares of Pharvaris common stock.

Insider Trade Summary 10b5-1

Exercise and Sale: 14,166 shares ($391K approx. pre-tax spread)

Exercise and Sale 5 txns

Insider Lu Peng

Role Chief Medical Officer

Sold 14,166 shs ($427K)

Approx. gross sale proceeds $427K

Approx. exercise cost $37K

Approx. pre-tax spread $391K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	14,023	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	143	$0.00	$0.00
Exercise	Common Stock	14,166	$2.59	$37K
Sale	Common Stock	14,023	$30.1637	$423K
Sale	Common Stock	143	$31.00	$4K

Holdings After Transaction: Stock Option (Right to Buy) — 205,308 contracts (Direct); Common Stock — 66,083 shares (Direct)

Footnotes (3)

F1. This is a scheduled exercise and sale from 10b5-1 trading plan.
F2. 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.
F3. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $30.00 to $30.99. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 14,166 shares Sale prices: $31.00 and $30.1637/share Options exercise price: $2.59/share +3 more

6 metrics

Shares sold 14,166 shares Common stock sold on May 1, 2026

Sale prices $31.00 and $30.1637/share Weighted average prices for 143 and 14,023 shares

Options exercise price $2.59/share Stock options exercised for 14,166 shares

Net buy/sell shares -14,166 shares Net-sell direction from transaction summary

Shares held after 66,083 shares Direct common stock ownership following transactions

Option expiration February 3, 2030 Expiration date for exercised stock options

Key Terms

Rule 10b5-1 trading plan, cashless exercise transaction, Stock Option (Right to Buy), weighted average sale price

4 terms

Rule 10b5-1 trading plan regulatory

"pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

cashless exercise transaction financial

"shares were sold in connection with the exercise of stock options in a cashless exercise transaction."

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

weighted average sale price financial

"The reported price represents a weighted average sale price for shares sold"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Pharvaris (PHVS) executive Lu Peng report in this Form 4?

Lu Peng, Chief Medical Officer of Pharvaris, reported exercising stock options for 14,166 shares at $2.59 and selling the same 14,166 shares in open-market transactions around $30–$31 per share under a Rule 10b5-1 trading plan.

How many Pharvaris (PHVS) shares did Lu Peng sell and at what prices?

Lu Peng sold a total of 14,166 Pharvaris common shares. Reported weighted average sale prices were approximately $31.00 for 143 shares and $30.1637 for 14,023 shares, with individual sale prices ranging from $30.00 to $30.99 per share.

What stock options did Lu Peng exercise in Pharvaris (PHVS)?

Lu Peng exercised options to buy 14,166 Pharvaris common shares at an exercise price of $2.59 per share. These options were part of a grant that vested 25% on February 3, 2021, with the remainder vesting in equal monthly installments over 48 months.

Was Lu Peng’s Pharvaris (PHVS) stock sale pre-planned?

Yes. The filing states the exercise and sale were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan. Such plans schedule trades in advance, making the timing more routine and reducing the informational value of short-term price movements.

How many Pharvaris (PHVS) shares does Lu Peng hold after these transactions?

After completing the option exercise and related sales, Lu Peng directly holds 66,083 shares of Pharvaris common stock. This figure reflects her remaining equity position following the May 1, 2026 exercise-and-sale transactions disclosed in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/05/2026 - 03:51 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lu Peng

(Last)

(First)

(Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON

MASSACHUSETTS

02421

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/01/2026		M⁽¹⁾		14,166	A	$2.59	80,249	D
Common Stock	05/01/2026		S⁽¹⁾		14,023	D	$30.1637⁽³⁾	66,226	D
Common Stock	05/01/2026		S⁽¹⁾		143	D	$31	66,083	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.59	05/01/2026		M⁽¹⁾			14,023	⁽²⁾	02/03/2030	Common Stock	245,308	$0	205,451	D
Stock Option (Right to Buy)	$2.59	05/01/2026		M⁽¹⁾			143	⁽²⁾	02/03/2030	Common Stock	245,308	$0	205,308	D

Explanation of Responses:

1. This is a scheduled exercise and sale from 10b5-1 trading plan.

2. 25% of the option vested on February 3, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

3. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares were sold in connection with the exercise of stock options in a cashless exercise transaction. The sales prices for the transactions ranged from $30.00 to $30.99. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

	/s/ Marnus Nel, Attorney-in-Fact for Peng Lu	05/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR